课题基金 / 基金详情

Cell-free hemoglobin-oxidized LDL-LOX-1 axis and microvascular hyperpermeability during sepsis

Cell-free hemoglobin-oxidized LDL-LOX-1 axis and microvascular hyperpermeability during sepsis
脓毒症期间无细胞血红蛋白氧化的 LDL-LOX-1 轴和微血管通透性过高
批准号:
10739620
负责人:
Jamie E Meegan
金额:
$14.02万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-08-01 至 2025-07-31
关键词:
AbbreviationsAcute Lung InjuryAcute Respiratory Distress SyndromeAdherens JunctionAntibodiesApoptoticAtherosclerosisAutomobile DrivingBindingBlood VesselsCREB1 geneCardiovascular DiseasesCell SeparationCellsCessation of lifeClinicalCyclic AMP-Responsive DNA-Binding ProteinDataEdemaEndothelial CellsEndotheliumErythrocytesFiltrationFunctional disorderGenerationsGoalsHaptoglobinsHemoglobinHumanImmune responseInfectionInflammation MediatorsInflammatoryInjectionsInjuryLaboratoriesLectinLectin ReceptorsLinkLipoproteinsLow Density Lipoprotein oxidationLungMAP Kinase GeneMatrix MetalloproteinasesMeasuresMediatingMembrane ProteinsMentorsMetalloproteasesMicrovascular DysfunctionMitogensMolecularMorbidity - disease rateMusOrganOxidantsPathogenesisPathologicPathway interactionsPatientsPeer ReviewPeptide HydrolasesPermeabilityPhasePhosphotransferasesPhysiologicalPlasmaPlasma CellsPositioning AttributePreparationPrevention strategyProteinsReceptor SignalingRegulationResearchResolutionRoleSepsisSignal PathwaySignal TransductionSmall Interfering RNATechnical ExpertiseTestingTight JunctionsTissuesTrainingUp-RegulationVascular Endothelial CellVascular EndotheliumWritingcareercell injuryclinically relevantendothelial dysfunctionex vivo perfusioninhibitorlung injurylung microvascular endothelial cellsmodel developmentmortalitymouse modelnew therapeutic targetnoveloxidationoxidized LDL receptorsoxidized low density lipoproteinp38 Mitogen Activated Protein Kinasepolymicrobial sepsisprogramsreceptorseptic patientsskillssystemic inflammatory responsetargeted treatmenttranslational studytreatment strategy

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT Sepsis, a dysregulated host response to infection with high morbidity and mortality, is characterized by a systemic inflammatory response and widespread vascular hyperpermeability leading to edema, organ dysfunction, and death. Lung vascular hyperpermeability in sepsis contributes to acute respiratory distress syndrome (ARDS), with no specific prevention or treatment strategies. Disruption of the microvascular endothelial cell (MVEC) barrier is a critical pathological feature of sepsis-induced lung injury driven by circulating inflammatory mediators, oxidants, and proteolytic enzymes. Our group has shown that plasma cell- free hemoglobin (CFH), released during sepsis due to red blood cell fragility, is a mechanistic driver of acute lung injury through induction of lung MVEC hyperpermeability. However, the cellular and molecular mechanisms are unknown. One potential mechanism by which CFH may disrupt the MVEC barrier is through its known ability to oxidize low-density lipoprotein (oxLDL). OxLDL binds and signals through its major endothelial receptor lectin-like oxidized LDL receptor 1 (LOX-1) to cause endothelial dysfunction. LOX-1 activation has been implicated in cardiovascular diseases such as atherosclerosis but its involvement in MVEC hyperpermeability during sepsis is unknown. Our preliminary data from patients with sepsis show that circulating CFH and oxLDL are tightly correlated with each other, MVEC injury markers, and mortality. However, little is known regarding LOX-1 receptor signaling leading to hyperpermeability, especially in the context of sepsis-induced injury to the lung microvasculature. This proposal aims to test the central hypothesis that MVEC hyperpermeability and lung injury during sepsis are mediated through oxidation of LDL by CFH to induce LOX-1 receptor signaling and ectodomain shedding. My career and long-term research goals are to establish an independent academic research program to identify novel signaling mechanisms regulating microvascular endothelial hyperpermeability during sepsis that can be targeted therapeutically for treatment of sepsis-induced organ dysfunction. During the mentored phase of this proposal, I will develop new physiologically relevant and translationally significant technical skills like ex vivo perfused human lung, lung filtration coefficient, endothelial cell isolation, and tissue-specific mouse model development, as well as gain expertise in lipoprotein and membrane protein pathophysiology. I will also enhance my proficiency in laboratory management, mentoring, peer review and writing. I have assembled a superb mentoring team to help me achieve these new skills and my career goals. The proposed research and training in this application will be crucial preparation for my transition to an independent academic research career and position me well to achieve my goal of becoming a leader in mechanistic and translational studies of microvascular dysfunction in sepsis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金